|
Day 2. Saturday, 27 August 2022 (8AM to 5PM)
|
|
Time
|
Title
|
Speakers
|
|
Moderators: Dr. Mohamed Riyas, Dr. Abdul Rehman Zar
|
|
8.00 am - 8.25 am
|
Head and Neck Cancer
(Abstract 6000): Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicenter, open-label, non-inferiority, randomized phase III trial
|
Dr. Hissa Al Abdulla
Senior Consultant Radiation Oncologist, NCCCR
|
|
8.25 am - 8.50 am
|
Head and Neck Cancer
(Abstract 6004): An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial)
|
Dr. Aladdin Kanbour
Senior Consultant Medical Oncologist, NCCCR
|
|
8.50 am - 9.15 am
|
Genitourinary Cancer - Kidney and Bladder
(Abstract 4516): Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
|
Dr. Abdul Rehman Zar.
Senior Consultant Medical Oncologist, NCCCR
|
|
9.15 am - 9.40 am
|
Genitourinary Cancer - Kidney and Bladder
(Abstract 4513): Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426
|
Dr. Al Hareth Al Khater
Senior Consultant
Medical Oncologist,
NCCCR
|
|
9.40 am - 10.05 am
|
Central Nervous System Tumors
(Abstract 2000): Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis
|
Dr. Mohamed Riyas
Senior Consultant Radiation Oncologist, NCCCR
|
|
10.05 am - 10.20 am
|
Coffee Break
|
|
Moderators: Dr. Al Hareth Al Khater , Dr. Reyad Mohsen
|
|
10.45 am - 11.10 am
|
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
(Abstract 8501): Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial
|
Dr. Reyad Mohsen,
Senior Consultant Medical Oncologist, NCCCR
|
|
11.10 am - 11.35 am
|
Lung Cancer - Non-Small Cell Metastatic
(Abstract 9004): Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A
|
Dr. Ammar Madani,
Associate Consultant Medical Oncologist, NCCCR
|
|
11.35 am - 12.00 pm
|
Clinical Science Symposium
(Abstract 109): Long-term effect of machine learning–triggered behavioral nudges on serious illness communication and end-of-life outcomes among patients with cancer: A randomized clinical trial
|
Dr. Ayman Allam,
Senior Consultant, Palliative Care,
NCCCR
|
|
12.00 pm - 12.25 pm
|
Clinical Science Symposium
(Abstract 110): Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM)
|
Dr. Azza Hassan,
Chief of Palliative Medicine and Fellowship, Senior Consultant, NCCCR
|
|
12.25 pm - 1.25 pm
|
Dhuhr Prayer & Lunch Break
|
|
Moderators: Dr. Kakil Rasul
|
|
1.25 pm - 1.50 pm
|
Gastrointestinal Cancer - Colorectal and Anal
(Abstract LBA5): Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer
|
Dr. Kakil Rasul,
Senior Consultant Medical Oncologist, NCCCR
|
|
1.50 pm - 2.15 pm
|
Gastrointestinal Cancer - Colorectal and Anal
(Abstract LBA100): Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial
|
Dr. Mai Mostafa
Consultant Medical Oncologist, NCCCR
|
|
2.15 pm - 2.40 pm
|
Gastroesophageal, Pancreatic, and Hepatobiliary
(Abstract 4004): A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211)
|
Dr. Aleem Akram
Consultant Medical Oncologist, NCCCR
|
|
2.40 pm - 3.05 pm
|
Gastroesophageal, Pancreatic, and Hepatobiliary
(Abstract 4003): Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
|
Dr.Alaaeldin Shablak,
Consultant Medical Oncologist, NCCCR
|
|
3.05 pm - 3.30 pm
|
Gastrointestinal Cancer - Colorectal and Anal
(Abstract 3503): Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer
|
Dr. Mohamed Sir,
Consultant Medical Oncologist, NCCCR
|
|
3.30 pm - 3.45 pm
|
Asr Prayer & Coffee Break
|
|
Moderators: Dr. Kakil Rasul, Dr. Azza Hassan
|
|
3.45 pm - 4.10 pm
|
Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary
(Abstract LBA4011): Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial
|
Dr. Arwa Isameldin,
Consultant Medical Oncologist, NCCCR
|
|
4.10 pm - 4.35 pm
|
Care Delivery and Regulatory Policy (Abstract 1515 -1516 -1517): Home Sweet Home: Bringing Cancer Care to the Patient
|
Dr. Anas Hamad,
Director of Pharmacy,
NCCCR
|
|
4.35 pm - 5.00 pm
|
Closing Remarks
|
Dr. Ussama Al Homsi,
Deputy Medical Director, Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR
|
